Activity from announced rounds
Alumni Ventures co-invests in startup rounds alongside an established lead investor. Its principal focus is pre-seed through Series B, with typical investments of $1 million to $3 million.
The firm generally joins on the lead investor’s terms, does not take a board seat and commits after a lead is secured. Founders do not need an alumni connection to qualify. This makes it a potential syndicate participant for a company that already has the core terms and leadership of its round in place.
Its platform team works on introductions to customers, hires and subsequent investors. Founders can request help through their investment team or the AVP Hub, including access to the firm’s alumni networks and commercial resources.
RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development.
Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health.
Automates curation and enrichment of real-world clinical data for pharmaceutical and life sciences research
Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy
Develops implantable Brain-Computer Interfaces (iBCIs) for neurological disorders
Provides metagenomic biosurveillance for poultry producers to detect disease threats early
Provides AI-powered commercial intelligence for Life Sciences organizations